Why the study?
Pimobendan's use in cats with HCM remains controversial due to lacking pharmacodynamic data and concerns regarding exacerbation of left ventricular outflow tract obstructions.
Does a single dose of pimobendan improve echocardiographic measures of cardiac function without exacerbating LVOT obstruction in cats with hypertrophic cardiomyopathy?
Does a single dose of pimobendan improve echocardiographic measures of cardiac function without exacerbating LVOT obstruction in cats with hypertrophic cardiomyopathy?
A single dose of pimobendan in cats with HCM improved left atrial function without exacerbating LVOT obstruction, suggesting it may not be contraindicated in this population.
Authors
No takes yet. Share an insight, caveat, or question.
May support further study of pimobendan in feline HCM; leaves open clinical translation from this animal model.
Oldach et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: